BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce that it has been invited to present at the Emerging Growth Conference on February 17, 2021.

The Emerging Growth Conference, premiering on February 17, 2021, is a live and interactive online event that will give existing shareholders and the investment community the opportunity to interact with the Company’s CEO, Dr. Ahmad Doroudian, in real time. 

Dr. Doroudian will present BetterLife’s upcoming plans and may subsequently open the floor for questions.  Please ask your questions during the event and Dr. Doroudian will do his best to get through all of them in the allotted amount of time.

BetterLife will be presenting at 2:30 PM Eastern time for 30 minutes.

Please register here to ensure you are able to attend the conference and receive any updates that are released.

https://attendee.gotowebinar.com/register/268751841082709007?source=Better+Life+Pharma%2C+Inc.+BETRF

If attendees are not able to join the event live on the day of the conference, an archived webcast will be made available on EmergingGrowth.com and a link will also be released by the Company after the event.

About the Emerging Growth Conference

Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets.  We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth.  Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community.  It is these companies that we strive to showcase through the Emerging Growth Conference.  Every other week, eight (8) companies will present to an entirely new demographic of audience who may become shareholders of the respective companies. 

About BetterLife Pharma Inc.

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of next generation psychedelic products for the treatment of mental disorders. Utilizing drug delivery platform technologies, BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus.

For further information please visit www.abetterlifepharma.com.

Contact:

Ahmad Doroudian, Chief Executive Officer
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 604-221-0595

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.